RATIONALE: Placement of an indwelling pleural catheter is an established modality for symptom relief and pleurodesis in the treatment of malignant pleural effusion. Concerns remain regarding possible infectious complications, risk of hemorrhage, and the rate of pleurodesis with the use of pleural catheters in the treatment of hematologic malignancies. OBJECTIVES: The goals of our study were: (1) to evaluate the safety and cumulative incidence of pleurodesis with indwelling pleural catheters for patients with hematologic malignancies, and (2) to evaluate overall survival of this cohort of patients with pleural effusions. METHODS: We performed a retrospective review of 172 patients with a hematologic malignancy who underwent placement of an indwelling pleural catheter between September 1997 and August 2011 at the University of Texas MD Anderson Cancer Center in Houston, Texas. A competing risk model analysis was used for complications and pleurodesis. Analysis was based on each patient's first intrapleural catheter. RESULTS: There were 172 patients with lymphoma (58%), acute (16%) or chronic leukemia (16%), or multiple myeloma (10%). The effusions were characterized as malignant (85.5%), infectious (4.1%), volume overload (4.7%), or therapy-related (4.7%). Chylothorax was found in 20.1%. Pleural biopsies were obtained from 13 patients. The cumulative incidence of all complications was 13.6%, and the cumulative incidence of all significant catheter-related complications was 9.5%. The incidence of empyema was 2.9%, and major bleeding (requiring transfusion or intervention) was 1.7%. Thirty-day procedure-associated mortality was 0.6%. The cumulative incidence of pleurodesis at 180 days was 50%, with a median time to pleurodesis of 81 days for the entire cohort. CONCLUSIONS: Indwelling pleural catheters appear to be safe for patients with hematologic malignancies. Complications and the cumulative incidence of pleurodesis are comparable to those reported for patients with solid organ malignancies.
RATIONALE: Placement of an indwelling pleural catheter is an established modality for symptom relief and pleurodesis in the treatment of malignant pleural effusion. Concerns remain regarding possible infectious complications, risk of hemorrhage, and the rate of pleurodesis with the use of pleural catheters in the treatment of hematologic malignancies. OBJECTIVES: The goals of our study were: (1) to evaluate the safety and cumulative incidence of pleurodesis with indwelling pleural catheters for patients with hematologic malignancies, and (2) to evaluate overall survival of this cohort of patients with pleural effusions. METHODS: We performed a retrospective review of 172 patients with a hematologic malignancy who underwent placement of an indwelling pleural catheter between September 1997 and August 2011 at the University of Texas MD Anderson Cancer Center in Houston, Texas. A competing risk model analysis was used for complications and pleurodesis. Analysis was based on each patient's first intrapleural catheter. RESULTS: There were 172 patients with lymphoma (58%), acute (16%) or chronic leukemia (16%), or multiple myeloma (10%). The effusions were characterized as malignant (85.5%), infectious (4.1%), volume overload (4.7%), or therapy-related (4.7%). Chylothorax was found in 20.1%. Pleural biopsies were obtained from 13 patients. The cumulative incidence of all complications was 13.6%, and the cumulative incidence of all significant catheter-related complications was 9.5%. The incidence of empyema was 2.9%, and major bleeding (requiring transfusion or intervention) was 1.7%. Thirty-day procedure-associated mortality was 0.6%. The cumulative incidence of pleurodesis at 180 days was 50%, with a median time to pleurodesis of 81 days for the entire cohort. CONCLUSIONS:Indwelling pleural catheters appear to be safe for patients with hematologic malignancies. Complications and the cumulative incidence of pleurodesis are comparable to those reported for patients with solid organ malignancies.
Authors: Saadia A Faiz; Lara Bashoura; Xiudong Lei; Keeran R Sampat; Tiffany C Brown; George A Eapen; Rodolfo C Morice; Alessandra Ferrajoli; Carlos A Jimenez Journal: Leuk Lymphoma Date: 2012-09-10
Authors: Momen M Wahidi; Chakravarthy Reddy; Lonny Yarmus; David Feller-Kopman; Ali Musani; R Wesley Shepherd; Hans Lee; Rabih Bechara; Carla Lamb; Scott Shofer; Kamran Mahmood; Gaetane Michaud; Jonathan Puchalski; Samaan Rafeq; Stephen M Cattaneo; John Mullon; Steven Leh; Martin Mayse; Samantha M Thomas; Bercedis Peterson; Richard W Light Journal: Am J Respir Crit Care Med Date: 2017-04-15 Impact factor: 21.405
Authors: Helen E Davies; Eleanor K Mishra; Brennan C Kahan; John M Wrightson; Andrew E Stanton; Anur Guhan; Christopher W H Davies; Jamal Grayez; Richard Harrison; Anjani Prasad; Nicola Crosthwaite; Y C Gary Lee; Robert J O Davies; Robert F Miller; Najib M Rahman Journal: JAMA Date: 2012-06-13 Impact factor: 56.272
Authors: Roberto F Casal; Lara Bashoura; David Ost; Hsienchang T Chiu; Saadia A Faiz; Carlos A Jimenez; Rodolfo C Morice; George A Eapen Journal: Am J Med Qual Date: 2012-07-03 Impact factor: 1.852
Authors: Kei Suzuki; Elliot L Servais; Nabil P Rizk; Stephen B Solomon; Camelia S Sima; Bernard J Park; Stefan S Kachala; Maria Zlobinsky; Valerie W Rusch; Prasad S Adusumilli Journal: J Thorac Oncol Date: 2011-04 Impact factor: 15.609
Authors: D Kirn; P Mauch; K Shaffer; G Pinkus; M A Shipp; W D Kaplan; N Tung; C Wheeler; C J Beard; G P Canellos Journal: J Clin Oncol Date: 1993-07 Impact factor: 44.544
Authors: Amelia O Clive; Brennan C Kahan; Clare E Hooper; Rahul Bhatnagar; Anna J Morley; Natalie Zahan-Evans; Oliver J Bintcliffe; Rogier C Boshuizen; Edward T H Fysh; Claire L Tobin; Andrew R L Medford; John E Harvey; Michel M van den Heuvel; Y C Gary Lee; Nick A Maskell Journal: Thorax Date: 2014-08-06 Impact factor: 9.139
Authors: Sofia Molina; Gabriela Martinez-Zayas; Paula V Sainz; Cheuk H Leung; Liang Li; Horiana B Grosu; Roberto Adachi; David E Ost Journal: Chest Date: 2021-05-11 Impact factor: 10.262
Authors: Jana Pospiskova; Lukas Smolej; David Belada; Martin Simkovic; Monika Motyckova; Alice Sykorova; Pavla Stepankova; Pavel Zak Journal: Orphanet J Rare Dis Date: 2019-01-09 Impact factor: 4.123
Authors: Alberto Fantin; Nadia Castaldo; Paolo Vailati; Giuseppe Morana; Daniele Orso; Luigi Vetrugno; Vincenzo Patruno Journal: Acta Biomed Date: 2021-11-03